chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Noticed elevated heart rate when I worked out for 48 hours after both doses; During one event I had to stop the workout to catch my breath; This is a spontaneous report from a contactable consumer (patient husband) or other non-healthcare professional. A female patient of an unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot number and expiration dates were not reported) dose 2 via an unspecified route of administration on an unspecified date as single dose and dose 1 of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot number: EN6204 and expiration dates were not reported) dose 1 via an unspecified route of administration in arm left on 08Apr2021 at 12:00 as single dose COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Patient had not taken any vaccination in four weeks duration neither any other medications prior to two weeks of vaccination. Patient did not have COVID-19 prior to vaccine and neither tested for COVID-19 post vaccination. It was reported that the patient had noticed elevated heart rate when she worked out. Her watch tracked 15- 20BPM (beats per minute) higher than normal (she does the exact same workout almost everyday) for 48 hours after both doses. During one event patient had to stop the workout to catch her breath. Given some of the reporting of heart inflammation reporter thought this would be helpful. Reporter wife had the exact same reaction. The patient underwent lab test procedure include Heart rate results elevated 15-20 BPM higher than normal. The events were reported as non-serious. No treatment was taken as a result of events. The outcome of all the events were reported as recovered on unknown date.   Follow-Up (01Jul2021): Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021598382 same reporter/AE/SD, different patients.
3 hrs p/vax devel fever 105.1 R & fussy; treated w/APAP q 4 hrs & tepid sponge bath; evaluated by MD; impression-viral infection; treatment children's Advil; 9JUN94 developed genl rash lasting 2 days;
within 15 minutes my throat started to get tight.  After 15 more minutes it was harder to swallow.  The nurses looked  at me and noticed hives on my chest, back, neck and up my face.  They drove me to the ER where they did an intramuscular shot of benedryl since they could not get an IV into my veins.  They tried 8 times between both arms and even had another nurse attempt.  Neither were successful.  They discharged me 3 hours or so later with prescribing me benedryl 25mg twice a day for three days.
Immunocompromised patient received the booster dose instead of the 3rd dose.; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Immunocompromised patient received the booster dose instead of the 3rd dose.) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Immunocompromised patient received the booster dose instead of the 3rd dose.). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Immunocompromised patient received the booster dose instead of the 3rd dose.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Information of concomitant medication was unknown. No treatment drugs were reported.
Completed covid vaccine series 1/8/2021, developed symptoms 3/31/21 and tested positive on 4/2/2021.
Information has been received from a registered pharmacist concerning an 85 year old female patient with no known allergies who on 13-DEC-2010, was vaccinated SQ with a single 0.65 ml dose of ZOSTAVAX (Merck) (lot# not reported). Concomitant therapy included SYNTHROID, ACIPHEX, LUNESTA, ATIVAN and aspirin. Pharmacist reported that on 20-DEC-2010, the patient returned to the pharmacy complaining of chills, nausea, itching on two locations on the back, between the shoulder blades and on the back at the waistline; as well as a rash at the injection site, described as raised, red and approximately 2x2 inches in size. There were not lab diagnostics studies performed. The patient sought unspecified medical attention. At the time of the report, the patient's outcome is unknown. Follow-up information has been received from the pharmacist who reported that the retired female patient was vaccinated with SQ with a 0.65 ml first dose of ZOSTAVAX (Merck) (Lot# 669408/1384Z), arm, on 13-DEC-2010, at 13:00. Pharmacist reported that unknown time on 14-DEC-2010 the patient experienced rash at the injection site with some itching, chills, nausea, rash on waist (Very light). In December 2010 the patient had recovered from these symptoms. No further information is available.
can barely move the arm; Pain on the arm,lots of pain throughout her body; This spontaneous case was reported by a patient and describes the occurrence of MOBILITY DECREASED (can barely move the arm) and MYALGIA (Pain on the arm,lots of pain throughout her body) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Feb-2021, the patient experienced MOBILITY DECREASED (can barely move the arm) and MYALGIA (Pain on the arm,lots of pain throughout her body). At the time of the report, MOBILITY DECREASED (can barely move the arm) and MYALGIA (Pain on the arm,lots of pain throughout her body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication was not provided.  Treatment medication was not provided.
Customer requested the Pfizer bivalent dose #5 and presented her immunization card , and she was given the immunization as it was requested. and confirmed at time of immunization the  Pfizer bivalent and the dose #. After she goes home she found another immunization card which shows she had already the bivalent on 10/04/22 and found out duplicated and called the pharmacy to inform us.
Inconsolable crying x 4hrs began 1 1/2 hrs after injection. Seen in ER, treated with Tylenol. Redness/swelling to injection site.
A legal complaint was received from an attorney who alleges that an 18 month old female received haemophilus B conjugate vaccine, Acel-Imune, and MMR vaccines on 4/23/97. According to the legal complaint, the child experienced unspecified injury as part of exposure to thimerosal. No further information was available.
Itching after1hr continues days using benadryl  alternate Atarax face legs chest head Pain injection site and multi joint achiness On going day3
A consumer reported that her 5 month old son received his 2nd dose of Prevnar and Hep-B vaccines on 7/23/01. Two days later, the child was hospitalized with sepsis and purpura. No further information was available at the time of this report. F/U info was rec'd on 9/18/01 the hepatitis B vaccine rec'd by the pt was Engerix B. An additional adverse event was reported high pitched crying. The pt was hospitalized for 8 days in an intensive care unit. He subsequently recovered.
Child developed light rash on abdomen on day 3 after MMR. Also stated on Augmentin for otitis media on same day. On day 12 developed macule rash over entire body, no fever, cough. Seen by the doctor, confirmed rash is vaccine related and is not contagious.
Approximately 9 days after vaccine given, on 07/06/2006, developed a fever of 101 degrees Fahrenheit, small erythematous papular rash. Complained of mild nausea now queasy, likely secondary to MMR.
redness & sl swelling @ rt upper arm 24 hrs p/DTP was given; no other sx, no fever, no pain;
Information has been received from a physician concerning a 26 year old female who on approximately 01-APR-2008 was vaccinated with the first dose of GARDASIL vaccine (yeast) 0.5 ml, IM. On approximately 22-APR-2008, the patient experienced urticaria and nasal allergic reaction 3 weeks after her 1st dose of GARDASIL vaccine (yeast). BENADRYL helped the symptoms. An allergy testing was performed by a specialist which showed she was allergic to dust and mold. The patient was getting ready to get her second dose, but was hesitating based on her allergic reaction. At the time of this report, the patient was recovering. Additional information has been requested.
4 X 6cm erythmea right bicep, fundus pulp ?? afebrile
My face started to go numb and feel tingly.  My ears also felt plugged, as if I were changing elevations.  The effects lasted for a little over an hour.
Threw up; Pain on my side like between my ribs; This is a spontaneous report received from a contactable consumer or other non-health care professional (patient). A 60-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number and Expiration date: Unknown), via an unspecified route of administration in an unspecified anatomical location on 21May2021 (at the age of 60-year-old), as single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number and Expiration date: Unknown) via an unspecified route of administration in an unspecified anatomical location on an unspecified date (at the age of 60-year-old) as a single dose for COVID-19 immunisation. The caller got the second dose on Friday afternoon, 21May2021, and she was perfectly fine at first. Later Friday, 21May2021, the caller was throwing up like crazy and that just stopped as of yesterday, 23May2021. The caller was throwing up all Friday afternoon and she could not stop. Now, the caller's muscles, like the ones that are in-between her ribs, are hurting. It especially hurts when the caller sits down and when she lays down. The patient wanted to know whether the muscle pain will go away. The outcome of the event vomiting was reported as resolved on 23May2021 and for pain was unknown.  Follow up needed, further information has been requested.
COVID 19 Treatment; COVID 19 Treatment; Interchange of vaccine products; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 76-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 12Sep2022 as dose 5 (booster), single (Lot number: GJ2524) at the age of 76 years, in right arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 11Apr2022 as dose 4 (booster), single (Lot number: 027l21a), in right arm, as dose 3 (booster) , single (Lot number: 706221a), in left arm, on 12Mar2022 as dose 2, single (Lot number: 002b21a), in left arm and on 12Feb2022 as dose 1, single (Lot number: 006m20a), in left arm for covid-19 immunisation. The patient's relevant medical history included: "sarcoidosis" (unspecified if ongoing); "high BP" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXIN; ATORVASTATIN; LISINOPRIL; OXYBUTYNIN; HYDROCHLOROTHIAZIDE; INDOMETHACIN [INDOMETACIN]; ASPIRIN [ACETYLSALICYLIC ACID]; VITAMIN B12 [CYANOCOBALAMIN]; VITAMIN D [COLECALCIFEROL]. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 12Sep2022, outcome "unknown"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Feb2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient was received Paxlovid as treatment. Date of start of drug 01Feb2023 and Date of last administration 05Feb2023. The patient was taking any other medications/products within 2 weeks of starting COVID-19 treatment was reported as yes. The patient previously receive a COVID-19 Vaccine.
Severe headache in the top of my head, severe muscle aches in every muscle in my body  increased in my thighs ( could not walk), joint paint in every joint of my body( my fingers ached), fever, sore throat, sinuses congestion and cough started 3/05/21. Weak, dizzy and fatigue. Symptoms lasted 4 days. I was bed ridden. Took Tylenol and NSAIDS ( which helped).
FLUZONE HD administered approximately 3:30P 9-22. Patient reported stiffness, general tiredness, some mild dizziness and came in 9-23 approximately 5pm with red warm rash on vaccinated arm extending about 5" down from vaccine site. Advised cold compress and BENAFRYL and seek medical care if not better, it worse or more generalized sx.
Patient suffered an acute myocardial infarction.  On 2/12/2021 at 0230 hrs he was awakened with severe left sided chest pain/tightness radiating into his jaw associated with shortness of breath.  He presented to the emergency department around 0330 hrs.  He underwent cardiac catheterization around 0600 hrs where is coronary anatomy was normal without obstruction.  His echocardiogram estimated his left ventricular ejection fraction to be 42%. He was started on appropriate medications and released home in good condition on 02/13/2021.
Arthralgia, myalgia with residual osteitis in the lateral humerus.  The swelling causes the deltoid in the left shoulder to pop back and forth across the osteitis cause aching, numbness, and minor tingling.
Off-balance at times/ felt like she was going to lose her balance when she got up in the morning; Sore tenderness in left arm few hours later; dizzy / unsteady on feet/light headiness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy / unsteady on feet/light headiness), BALANCE DISORDER (Off-balance at times/ felt like she was going to lose her balance when she got up in the morning) and VACCINATION SITE PAIN (Sore tenderness in left arm few hours later) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No specified medical history has been reported.     On 19-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, the patient experienced DIZZINESS (dizzy / unsteady on feet/light headiness) and VACCINATION SITE PAIN (Sore tenderness in left arm few hours later). On 21-Apr-2021, the patient experienced BALANCE DISORDER (Off-balance at times/ felt like she was going to lose her balance when she got up in the morning). On 19-Apr-2021, VACCINATION SITE PAIN (Sore tenderness in left arm few hours later) had resolved. On 21-Apr-2021, DIZZINESS (dizzy / unsteady on feet/light headiness) had resolved and BALANCE DISORDER (Off-balance at times/ felt like she was going to lose her balance when she got up in the morning) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications provided No treatment information was provided   Most recent FOLLOW-UP information incorporated above includes: On 22-May-2021: NNI_No new information On 22-Jul-2021: follow up received contains No new information.
Initial report was received from a healthcare professional on 06 August 2013. A 53-year-old male patient had received an injection of ADACEL, lot number C4424AA, on 14 June 2013 (route and site not reported). On 23 June 2013, 9 days later, the patient began to experience tingling of hands and symptoms that progressed to an inability to walk. The patient was seen at the emergency room and diagnosed with GBS. The patient was discharged to home (date not reported). On an unspecified date, the patient became worse with difficulty breathing and returned to the hospital and was admitted. The patient is currently discharged from the hospital and using a walker for ambulation. The patient had no illness at the time of vaccination and no known drug allergies. Outcome was not recovered. Documents held by sender: None.
Dizzy; Low Grade Fever; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizzy) and PYREXIA (Low Grade Fever) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, the patient experienced DIZZINESS (Dizzy) and PYREXIA (Low Grade Fever). At the time of the report, DIZZINESS (Dizzy) had not resolved and PYREXIA (Low Grade Fever) outcome was unknown.            No concomitant medications were provided.  No treatment was reported for the events.
Hives; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J202A) for COVID-19 vaccination.     The patient's past medical history included Polycystic ovarian syndrome since an unknown date. Concomitant products included MAGNESIUM and SPIRONOLACTONE for an unknown indication.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced URTICARIA (Hives). At the time of the report, URTICARIA (Hives) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Shingles shot and several years later l still got the shingles/ Suspected vaccination failure; Shingles; Very painful; This case was reported by a consumer and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, several years after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure, shingles and pain were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by patient. The age at vaccination was not reported. The patient received the shingles shot and several years later developed the shingles. The patient was told that it was a light case, but to the patient they were very painful. This case was considered to be a suspected vaccination failure case, as the details regarding being full vaccination schedule and laboratory confirmation for shingles were unknown.
Vaccine #1 gave me a scratchy, tight, throat. Vaccine #2 caused me to break out in hives and a rash, with heart palpitations (I filed a separate report for this event, but forgot to add the adverse symptoms). Symptoms began within 5 minutes of the vaccine. I was given Benadryl. I am in my 2nd pregnancy, due 09/15/2021, and am also breast feeding my 5 month old.
The patient was administered an improperly stored dose of ROTATEQ; This spontaneous report was received from a nurse referring to a patient of unknown age. The patient's pertinent medical history, concomitant therapies and drug reactions or allergies were not reported.  On 26-MAY-2020, the patient received an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S013890 with expiration date 14-FEB-2021, oral for prophylaxis. The vaccine was exposed to a temperature of 12.1 centigrade (C) during a time frame of 16 hours and 11 minutes, which was detected by a digital data logger. There were no previous temperature excursions.
Tightness around eyes, eyelids itching, breathing swallow, and stating, ?don?t feel right.? Vital  160/98, pulse 65 95%ra.  Put given Benadryl 1tab with relief of sx.
Few hours after PPV23--small knot and discomfort.  18 hours after shot--2 cm redness on site with warmth to touch.  24 hours after shot--3 cm redness on site, warm to touch, tender; some wheezing.  ti hours after shot--fever, wheezing, body chills and 4 cm redness with tenderness at site, warm to touch.
sore left arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (left arm) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042B21A) for COVID-19 vaccination.     The patient's past medical history included Skin melanoma removed in 2020 and Laser therapy.    On 11-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Apr-2021, after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MYALGIA (left arm). At the time of the report, MYALGIA (left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant products was provided by the reporter. No treatment information was provided by the reporter.   This case was linked to MOD-2021-294294 (Patient Link).
pt recv vax 23SEP97 & about 16hr p/vax pt reportedly exp fever 104, sz, hallucinations & h/a severe;pt missed school following day however was not reported as being hosp, not seen by local MD nor seen in ER:
chills; temperature of 102 degrees F; headache; muscle aches; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills), PYREXIA (temperature of 102 degrees F), HEADACHE (headache) and MYALGIA (muscle aches) in a 69-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     Concomitant products included ESOMEPRAZOLE SODIUM (NEXIUM [ESOMEPRAZOLE SODIUM]), ROSUVASTATIN CALCIUM (CRESTOR), CLOPIDOGREL BISULFATE (PLAVIX), METOPROLOL SUCCINATE (TOPROL), MULTIVITAMIN [VITAMINS NOS], FISH OIL, UBIDECARENONE (COQ), ACETYLSALICYLIC ACID (BABY ASPIRIN) and CALCIUM for an unknown indication.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, the patient experienced CHILLS (chills), PYREXIA (temperature of 102 degrees F), HEADACHE (headache) and MYALGIA (muscle aches). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 13-Feb-2021, CHILLS (chills), PYREXIA (temperature of 102 degrees F), HEADACHE (headache) and MYALGIA (muscle aches) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       This case was linked to MOD-2021-030499.; Sender's Comments:  MOD-2021-030499:crosslink